{"id":"carvedilol-cr","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Dizziness"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Bradycardia"},{"rate":"5-10","effect":"Hypotension"},{"rate":"5","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Erectile dysfunction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carvedilol blocks beta-1 and beta-2 adrenergic receptors as well as alpha-1 adrenergic receptors, reducing sympathetic nervous system activity. This dual action decreases heart rate and contractility while also causing vasodilation, lowering blood pressure and improving cardiac efficiency in heart failure and hypertension. The CR (controlled-release) formulation provides sustained drug delivery for once-daily dosing.","oneSentence":"Carvedilol CR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:19.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure with reduced ejection fraction"},{"name":"Left ventricular dysfunction following myocardial infarction"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT00430040","phase":"PHASE4","title":"Vascular Benefits of Adding CarvedilolCR to Type2 Diabetic Patients on ACEI.","status":"TERMINATED","sponsor":"University at Buffalo","startDate":"2007-02","conditions":"Diabetes Mellitus, Type 2, Hypertension","enrollment":14},{"nctId":"NCT00323037","phase":"PHASE3","title":"A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure","status":"COMPLETED","sponsor":"CTI-1, LLC","startDate":"2006-03","conditions":"Congestive Heart Failure","enrollment":318},{"nctId":"NCT00657241","phase":"PHASE3","title":"Cardioprotective Benefits of Carvedilol-CR or Valsartan Added to Lisinopril","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2008-04","conditions":"Hypertension","enrollment":30},{"nctId":"NCT03861598","phase":"EARLY_PHASE1","title":"Carvedilol With Chemotherapy in Second Line Glioblastoma and Response of Circulating Tumor Cells","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2019-07-19","conditions":"Glioblastoma Multiforme, Glioblastoma","enrollment":4},{"nctId":"NCT01009918","phase":"PHASE2","title":"Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab","status":"COMPLETED","sponsor":"University of South Florida","startDate":"2010-03","conditions":"Breast Cancer, Cardiac Toxicity","enrollment":468},{"nctId":"NCT02357004","phase":"NA","title":"Mechanisms of Refractory Hypertension (Carvedilol)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2015-02","conditions":"Hypertensive","enrollment":""},{"nctId":"NCT00553969","phase":"PHASE1, PHASE2","title":"Efficacy of Coreg CR and Lisinopril on Markers for Cardiovascular Functional and Structural Disease","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2007-11","conditions":"Pre-hypertension","enrollment":101},{"nctId":"NCT00669279","phase":"PHASE4","title":"Effect of Carvedilol Controlled-Release (CR) and Atenolol on Central Blood Pressure","status":"COMPLETED","sponsor":"University of Florida","startDate":"2008-04","conditions":"Hypertension","enrollment":41},{"nctId":"NCT00508365","phase":"PHASE1","title":"Evaluation of Potential for Orthostatic Hypotension in Elderly Hypertensives","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09-25","conditions":"Hypertension","enrollment":62},{"nctId":"NCT00624065","phase":"PHASE3","title":"Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03","conditions":"Hypertension","enrollment":348},{"nctId":"NCT00347360","phase":"PHASE3","title":"The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-07","conditions":"Hypertension","enrollment":654},{"nctId":"NCT00108082","phase":"PHASE3","title":"The CLEVER Study - Coreg And Left Ventricular Mass Regression","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-01","conditions":"Hypertrophy, Left Ventricular","enrollment":287},{"nctId":"NCT00524134","phase":"PHASE2, PHASE3","title":"P-glycoprotein Inhibition as Adjunct Treatment for Medically Refractory Epilepsy.","status":"TERMINATED","sponsor":"Columbia University","startDate":"2008-12","conditions":"Epilepsy","enrollment":6},{"nctId":"NCT01171183","phase":"PHASE2","title":"Carvedilol for Psychostimulant Dependence","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2010-08","conditions":"Cocaine Dependence, Cocaine Withdrawal","enrollment":32},{"nctId":"NCT01316952","phase":"","title":"Coreg and HSRs-Updated Analysis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-06","conditions":"Hypersensitivity","enrollment":1},{"nctId":"NCT00459056","phase":"PHASE3","title":"The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients","status":"COMPLETED","sponsor":"St. Paul Heart Clinic","startDate":"2007-04","conditions":"Abdominal Obesity, Hypertension","enrollment":25},{"nctId":"NCT00272805","phase":"PHASE3","title":"Drug Compliance and Quality of Life in Patients With Heart Failure Dosed With Either Once-daily or Twice-daily Coreg","status":"COMPLETED","sponsor":"Cardiovascular Clinical Sciences Inc","startDate":"2005-10","conditions":"Chronic Heart Failure","enrollment":400},{"nctId":"NCT01587638","phase":"","title":"Use of Beta-blockers and Risk of New Onset Diabetes","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Hypertension","enrollment":12336},{"nctId":"NCT00732511","phase":"PHASE4","title":"Coreg CR, Blood Vessel Stiffness and Blood Vessel Function","status":"UNKNOWN","sponsor":"State University of New York - Downstate Medical Center","startDate":"2008-04","conditions":"Endothelial Function, Diabetes Mellitus, Hypertension","enrollment":40},{"nctId":"NCT00537043","phase":"PHASE1","title":"A Study to Compare COREG CR to COREG CR Fixed-dose Combination in Patients With High Blood Pressure","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Hypertension","enrollment":24},{"nctId":"NCT00552708","phase":"PHASE1","title":"A Study Investigating the Bioequivalence of the Fixed Dose Combination of COREG CR to COREG CR and ZESTRIL.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-09","conditions":"Hypertension","enrollment":55},{"nctId":"NCT00557128","phase":"PHASE1","title":"Study to Examine the Effect of Food on the Pharmacokinetics of the Fixed Dose Combination of COREG CR and Lisinopril.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11","conditions":"Hypertension","enrollment":24},{"nctId":"NCT00549510","phase":"PHASE1","title":"Study to Investigate Dose Proportionality of the Fixed Dose Combination of COREG CR and Lisinopril.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Hypertension","enrollment":29},{"nctId":"NCT00556920","phase":"PHASE1","title":"Study to Demonstrate the Bioequivalence of the Fixed Dose Combination of COREG CR™ and Lisinopril to Its Components","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10","conditions":"Hypertension","enrollment":50}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"BRADYCARDIA"},{"count":2,"reaction":"DRUG INEFFECTIVE"},{"count":2,"reaction":"HYPERSENSITIVITY"},{"count":1,"reaction":"AGGRESSION"},{"count":1,"reaction":"BACK PAIN"},{"count":1,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":1,"reaction":"BRONCHOSPASM"},{"count":1,"reaction":"CARDIAC FAILURE CONGESTIVE"},{"count":1,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":1,"reaction":"CONFUSIONAL STATE"}],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Coreg CR","oral carvedilol in esclating doses"],"phase":"marketed","status":"active","brandName":"Carvedilol CR","genericName":"Carvedilol CR","companyName":"University of Florida","companyId":"university-of-florida","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carvedilol CR is a non-selective beta-blocker with alpha-1 blocking activity that reduces heart rate, blood pressure, and cardiac workload. Used for Hypertension, Heart failure with reduced ejection fraction, Left ventricular dysfunction following myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}